TY  - JOUR
AU  - Montero-Vilchez, Trinidad
AU  - Cuenca-Barrales, Carlos
AU  - Rodriguez-Tejero, Andrea
AU  - Martinez-Lopez, Antonio
AU  - Arias-Santiago, Salvador
AU  - Molina-Leyva, Alejandro
PY  - 2022
DO  - 10.3390/jcm11041007
SN  - 2077-0383
UR  - http://hdl.handle.net/10668/21240
T2  - Journal of clinical medicine
AB  - Adalimumab is currently the only biological medicine approved by the FDA for the treatment of hidradenitis suppurativa (HS). The breakout of biosimilar drugs made them more accessible due to their impact on pharmacoeconomics. However, packaging,...
LA  - en
PB  - MDPI AG
KW  - adalimumab
KW  - biosimilar
KW  - hidradenitis suppurativa
KW  - switching
KW  - Humans
KW  - Biosimilar Pharmaceuticals
KW  - Excipients
KW  - Retrospective Studies
KW  - Economics, Pharmaceutical
KW  - Odds Ratio
KW  - Hospitals
TI  - Switching from Adalimumab Originator to Biosimilar: Clinical Experience in Patients with Hidradenitis Suppurativa.
TY  - research article
VL  - 11
ER  -